Low-Dose Naltrexone

Low-Dose Naltrexone (LDN) refers to the off-label use of naltrexone at significantly lower doses than those approved by the U.S. Food and Drug Administration (FDA) for treating opioid and alcohol dependence. While standard naltrexone doses typically range from 50 mg to 300 mg daily, LDN doses are usually between 0.5 mg and 4.5 mg. The exact mechanisms through which LDN exerts its effects are not fully understood, but current hypotheses involve its temporary blockade of opioid receptors, leading to a compensatory upregulation of endogenous opioid production and receptor sensitivity. Naltrexone is an opioid antagonist, meaning it blocks opioid receptors in the brain and body. At standard doses, this action is sustained, preventing exogenous opioids from binding and reducing cravings for alcohol. At very low doses, however, this blockade is believed to be transient, typically lasting only a few hours. This brief blockade is thought to trigger adaptive responses in the body, which may include modulation of the immune system and anti-inflammatory effects. LDN has garnered interest for its potential application in a range of conditions, particularly those involving immune system dysfunction, chronic pain, and certain neurological disorders. It is important to emphasize that LDN is an off-label use of naltrexone, meaning that while naltrexone itself is an FDA-approved drug, its use at these low doses for conditions other than opioid or alcohol dependence is not specifically approved by the FDA. Prescribing clinicians typically require specialized knowledge and justification for its use in these contexts. (FDA Naltrexone Label, DrugBank)